2月21日 - ** 医疗技术公司GlaukosGKOS.N股价盘前下跌11.2%，至139.7美元。
** 该公司周四发布 (link)，第四季度净亏损2220万美元，华尔街预计亏损2080万美元。
** GKOS 公布第四季度营收为 1.055 亿美元，预计为 1.007 亿美元。
** 公司预计 2025 年销售额在 4.75 亿美元至 4.85 亿美元之间，预期为 4.798 亿美元。
** GKOS 的主导产品是 iStent inject W，这是一种用于治疗青光眼的设备，青光眼是一种损害视神经的眼病。
** 股价在过去 12 个月中上涨了 75.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.